Please login to the form below

Not currently logged in
Email:
Password:

Innate Pharma

This page shows the latest Innate Pharma news and features for those working in and with pharma, biotech and healthcare.

Innate Pharma and AstraZeneca take monalizumab into phase 3

Innate Pharma and AstraZeneca take monalizumab into phase 3

Innate Pharma’s lead candidate monalizumab – which is licensed by AstraZeneca – is heading for a pivotal phase 3 clinical trial. . ... Innate Pharma.

Latest news

  • France’s Innate Pharma eyes $100m Nasdaq IPO France’s Innate Pharma eyes $100m Nasdaq IPO

    Would help fund development of antibody-based immunotherapies. Innate Pharma is seeking to raise $100m via a public listing on the Nasdaq that would help fund development of its antibody-based ... Both are thought to have potential in solid tumours.

  • AZ invests more in IO with Transgene oncolytic virus deal AZ invests more in IO with Transgene oncolytic virus deal

    It signed a deal with France’s Innate Pharma last October (centred on its anti-NKG2A antibody, monalizumab (IPH2201), and yesterday added an alliance with another French biotech, Transgene. ... cell death, and also by delivering a potent payload in a

  • AZ swells immuno-oncology pipeline with Innate deal AZ swells immuno-oncology pipeline with Innate deal

    Deal gives access to natural killer cell immunotherapy. AstraZeneca has enlisted the aid of France’s Innate Pharma as it tries to make up ground in immuno-oncology, licensing a ... For another $20m, AZ also gets an option on four other immuno-oncology

  • Inside the patient-centricity bubble Inside the patient-centricity bubble

    The hybrid model. However, ringing true to pharma, innovation comes at a price. ... Making an innate plea to pharma, he urged the industry to “stop thinking binary”.

  • Bad news for Innate Pharma as BMS-backed drug stumbles Bad news for Innate Pharma as BMS-backed drug stumbles

    Lirilumab combination fails to show additional benefit in SCCHN patients. French biotech Innate Pharma says it can’t see a development path forward for its lead cancer drug lirilumab after another ... and Innate indicated at the time that it was

More from news
Approximately 5 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    hepatitis B virus (HBV). Strategic. collaboration ‐. development. $445m. Innate Pharma/. ... Acquisition. $244m. Zealand/. Royalty Pharma. Royalty streams and milestones for Soliqua 100/33/.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    and Innate Pharma (IPH53) – both of which work by blocking immunosuppressive mechanisms in the tumour microenvironment. ... up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug (AZD2098) originally

  • Deal Watch January 2016 Deal Watch January 2016

    The second deal closed by Sanofi was with Innate Pharma to create new bispecific antibodies, which aim to kill tumour cells through the activation of NKp46. ... 502.3. Innate Pharma/ Sanofi. Collaboration . Collaboration to develop 2 bispecific NK cell

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    Gene therapy platform - CV diseases. 2, 300. Innate Pharma / AstraZeneca. ... 225. Intec Pharma/ Undisclosed Company. R&D collaboration plus option. Accordian Pill (gastro retentive delivery system).

  • Pharma deals in April 2015 Pharma deals in April 2015

    Continuing to build the oncology portfolio and looking to score a win with a combination therapy, AZ in-licensed Innate Pharma's IPH2201 for both monotherapy and also in combination with ... Roche has also been forging an immunotherapy alliance this month

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics